ArticleBMC rheumatology2025

Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis.

Qi Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.